Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Technologies, The Rockefeller University, Duke University, Emory University, Rosetta Inpharmatics, Illumina

Premium
Third Wave Technologies of Madison, Wis., has received US Patent No. 7,432,048, “Reactions on a solid surface.” The patent describes methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. Specifically, the patent relates to methods for forming a nucleic acid cleavage structure on a solid support, including a column, bead, microplate, or microarray, and cleaving the nucleic acid cleavage structure in a site-specific manner.
 

 
The Rockefeller University of New York; Duke University of Durham, NC; and Emory University of Atlanta have received US Patent No. 7,432,052, “Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrome and associated disorders.” The patent claims methods for identifying and modulating RNA transcripts or genes involved in fragile X syndrome and other associated disorders. RNA targets for FMRP have been identified by a novel monoclonal antibody to FMRP, and a consensus sequence for the RNA binding region has been identified. The identified sequences can be assayed for a role in fragile X or other related syndromes and arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are also claimed.
 

 
Rosetta Inpharmatics of Seattle has received US Patent No. 7,432,084, “Methods for preparing nucleic acid samples.” The patent claims methods for synthesizing nucleic acid molecules by: a) using an RNA template to enzymatically synthesize a first DNA molecule that is complementary to at least 50 contiguous bases of the RNA template; b) using the first DNA molecule as a template to enzymatically synthesize a second DNA molecule, forming a double-stranded DNA molecule where the first DNA molecule is hybridized to the second DNA molecule; c) using the first or second DNA molecule of the double-stranded DNA molecule as a template to enzymatically synthesize a first RNA molecule that is complementary to either the first DNA molecule or to the second DNA molecule; and d) using the first RNA molecule as a template to enzymatically synthesize a third DNA molecule that is complementary to the first RNA molecule. The patent also provides processed DNA samples prepared according to the method for synthesizing a preparation of nucleic acid molecules, as well as methods for hybridizing a processed DNA sample to a population of immobilized nucleic acid molecules.
 

 
Illumina has received US Patent No. 7,433,123, “Optical identification element having non-waveguide photosensitive substrate with diffraction grating therein.” The patent describes an optical identification element, also known as a microbead, which is made from pieces of an optical fiber or substrate that includes an inner core or region being surrounded by an outer cladding region. The optical fiber or substrate has an identification code imparted inside containing coded information. The identification code may be in the form of a Bragg grating inscribed or written in either the inner core or outer cladding. Additionally, the optical identification element may be microscopic in size having a length in a range of 1 to 1,000 microns or smaller; or for larger applications may have a length of 1.0 to 1,000 millimeters or more. The outer diameter may be as small as less than 1,000 microns, as well as in a range of 1.0 to 1,000 millimeters for larger applications, the patent states.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.